Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung ...
MarketBeat on MSN
GRAIL's Galleri test cuts stage 4 cancer diagnoses in study despite missed endpoint
Key Points Interested in GRAIL, Inc.? Here are five stocks we like better. GRAIL said its Galleri blood test showed it can ...
Grail executives were upbeat on study results for the Galleri multi-cancer early detection test, while ASCO said more ...
At the 2026 ASCO Annual Meeting, GRAIL reported full results from the NHS-Galleri and PATHFINDER 2 studies, showing its Galleri blood test shifted cancer detection toward earlier stages and reduced ...
Medical Device Network on MSN
ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection
Findings from a study of Veracyte’s Prosigna genomic assay and GRAIL’s multi-cancer early detection test were presented at ...
GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On June 18, GRAIL announced positive top-line performance and safety results from the pre-specified analysis of ...
Good day, ladies and gentlemen, and welcome to today's GRAIL analyst call. [Operator Instructions] Please be advised that this conference call is being recorded. GRAIL Investor Relations. Please begin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results